Is macituximab/magenex chemotherapy or targeted therapy?

Margetuximab is a typical targeted therapy drug, not a chemotherapy drug in the traditional sense. It is a monoclonal antibody biological agent and is specially developed for patients with HER2-positive breast cancer. HER2 is a receptor protein located on the cell membrane. Overexpression can lead to accelerated proliferation of breast cancer cells. By specifically binding to the HER2 receptor, margetuximab not only blocks the signaling pathway, but also activates natural killer (NK) cells and macrophages in the body's immune system to achieve antibody-dependent cellular cytotoxicity (ADCC), thereby accurately killing tumor cells.

Unlike chemotherapy drugs, chemotherapy usually works by non-selectively killing rapidly proliferating cells, which causes damage to both tumor cells and normal cells. Therefore, side effects are more obvious, such as hair loss, bone marrow suppression, and gastrointestinal reactions. Targeted therapies such as margetuximab, through molecular specific recognition of tumor cells, are precise and can reduce toxicity to normal tissues to a certain extent while improving treatment selectivity and tolerance.

Margetuximab is often used clinically in combination with chemotherapy to enhance the therapeutic effect, especially in patients whose disease progresses after trastuzumab treatment. Combination chemotherapy can provide rapid killing when the tumor load is high, while targeted monoclonal antibodies can inhibit tumor development in the long term by specifically recognizing tumor cells and mobilizing the immune system. This combination strategy allows patients to obtain the precision of targeted therapy while taking into account the broad-spectrum killing effect of chemotherapy, thereby achieving better clinical benefits in the management of advanced HER2-positive breast cancer.

In short, margituximab is essentially a targeted therapy, which achieves precise control of breast cancer cells by specifically acting onHER2 receptors and enhancing immune effects. It is not a chemotherapy drug, but it is often combined with chemotherapy in clinical applications to provide individualized and precise treatment plans for patients with HER2-positive breast cancer.

Reference materials:https://www.margenza.com/